Epigenetically - Targeted therapies for the treatment of hematological malignancies

Current Medicinal Chemistry

Volumn 18, Issue 12, 2011, Pages 1757-1764

  Georgiou, E ^a   Kouidou, S ^b  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

DNMT inhibitors; Epigenetics; HDAC inhibitors; Hematological malignancies

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROXYUREA; IMATINIB; JNJ 26481585; LENALIDOMIDE; MOCETINOSTAT; ONX 0912; PANOBINOSTAT; RESMINOSTAT; ROMIDEPSIN; THALIDOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ARTICLE; BURKITT LYMPHOMA; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EPIGENETICS; FATIGUE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; MUTATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; VOMITING;

DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 79955689580     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795496791     Document Type: Article

References (133)

1. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell 2007, 128 (4), 683-692. (Pubitemid 46273572)
2. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28 (10), 1057-1068.
3. Sharma, S.; Kelly, T. K.; Jones, P. A. Epigenetics in cancer. Carcinogenesis 2010, 31 (1), 27-36.
4. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196 (2), 261-282. (Pubitemid 17122132)
5. Malousi, A.; Maglaveras, N.; Kouidou, S. Intronic CpG content and alternative splicing in human genes containing a single cassette exon. Epigenetics. 2008, 3 (2), 69-73.
6. Jones, P. A.; Laird, P. W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21 (2), 163-167. (Pubitemid 29070360)
7. Irizarry, R. A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, M.; Webster, M.; Ji, H.; Potash, J. B.; Sabunciyan, S.; Feinberg, A. P. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41 (2), 178-186.
8. Doi, A.; Park, I. H.; Wen, B.; Murakami, P.; Aryee, M. J.; Irizarry, R.; Herb, B.; Ladd-Acosta, C.; Rho, J.; Loewer, S.; Miller, J.; Schlaeger, T.; Daley, G. Q.; Feinberg, A. P. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 2009, 41 (12), 1350-1353.
9. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128 (4), 693-705. (Pubitemid 46273577)
10. Bernstein, B. E.; Meissner, A.; Lander, E. S. The mammalian epigenome. Cell 2007, 128 (4), 669-681. (Pubitemid 46273573)
11. Esteller, M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin. Immunol. 2003, 109 (1), 80-88. (Pubitemid 37324745)
12. Ivascu, C.; Wasserkort, R.; Lesche, R.; Dong, J.; Stein, H.; Thiel, A.; Eckhardt, F. DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas. Int. J. Biochem. Cell Biol. 2007, 39 (7-8), 1523-1538. (Pubitemid 47031029)
13. Sakashita, K.; Koike, K.; Kinoshita, T.; Shiohara, M.; Kamijo, T.; Taniguchi, S.; Kubota, T. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. J. Clin. Invest 2001, 108 (8), 1195-1204. (Pubitemid 32995378)
14. Ji, H.; Ehrlich, L. I.; Seita, J.; Murakami, P.; Doi, A.; Lindau, P.; Lee, H.; Aryee, M. J.; Irizarry, R. A.; Kim, K.; Rossi, D. J.; Inlay, M. A.; Serwold, T.; Karsunky, H.; Ho, L.; Daley, G. Q.; Weissman, I. L.; Feinberg, A. P. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467 (7313), 338-342.
15. Rincon-Arano, H.; Guerrero, G.; Valdes-Quezada, C.; Recillas-Targa, F. Chicken alpha-globin switching depends on autonomous silencing of the embryonic pi globin gene by epigenetics mechanisms. J. Cell Biochem. 2009, 108 (3), 675-687.
16. Fang, X.; Yin, W.; Xiang, P.; Han, H.; Stamatoyannopoulos, G.; Li, Q. The higher structure of chromatin in the LCR of the beta-globin locus changes during development. J. Mol. Biol. 2009, 394 (2), 197-208.
17. Fathallah, H.; Portnoy, G.; Atweh, G. F. Epigenetic analysis of the human alpha- and beta-globin gene clusters. Blood Cells Mol. Dis. 2008, 40 (2), 166-173. (Pubitemid 351227427)
18. Xu, C. R.; Feeney, A. J. The epigenetic profile of Ig genes is dynamically regulated during B cell differentiation and is modulated by pre-B cell receptor signaling. J. Immunol. 2009, 182 (3), 1362-1369.
19. Kuang, F. L.; Luo, Z.; Scharff, M. D. H3 trimethyl K9 and H3 acetyl K9 chromatin modifications are associated with class switch recombination. Proc. Natl. Acad. Sci. U. S. A 2009, 106 (13), 5288-5293.
20. Milani, L.; Lundmark, A.; Kiialainen, A.; Nordlund, J.; Flaegstad, T.; Forestier, E.; Heyman, M.; Jonmundsson, G.; Kanerva, J.; Schmiegelow, K.; Soderhall, S.; Gustafsson, M. G.; Lonnerholm, G.; Syvanen, A. C. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010, 115 (6), 1214-1225.
21. Walker, B. A.; Wardell, C. P.; Chiecchio, L.; Smith, E. M.; Boyd, K. D.; Neri, A.; Davies, F. E.; Ross, F. M.; Morgan, G. J. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011, 117(2), 553-562.
22. Stumpel, D. J.; Schneider, P.; van Roon, E. H.; Boer, J. M.; de, L. P.; Valsecchi, M. G.; de Menezes, R. X.; Pieters, R.; Stam, R. W. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009, 114 (27), 5490-5498.
23. Hrodek, O.; Vesely, J. 5-azacytidine in childhood leukemia. Neoplasma 1971, 18 (5), 493-503.
24. Karon, M.; Sieger, L.; Leimbrock, S.; Finklestein, J. Z.; Nesbit, M. E.; Swaney, J. J. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973, 42 (3), 359-365.
25. Silverman, L. R.; McKenzie, D. R.; Peterson, B. L.; Holland, J. F.; Backstrom, J. T.; Beach, C. L.; Larson, R. A. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006, 24 (24), 3895-3903. (Pubitemid 46630737)
26. Kaminskas, E.; Farrell, A. T.; Wang, Y. C.; Sridhara, R.; Pazdur, R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005, 10 (3), 176-182. (Pubitemid 40463154)
27. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; Gore, S. D.; Seymour, J. F.; Bennett, J. M.; Byrd, J.; Backstrom, J.; Zimmerman, L.; McKenzie, D.; Beach, C.; Silverman, L. R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10 (3), 223-232.
28. Fenaux, P.; Ades, L. Review of azacitidine trials in Intermediate-2-and Highrisk myelodysplastic syndromes. Leuk. Res. 2009, 33 Suppl 2, S7-11.
29. Kantarjian, H. M.; O'Brien, S.; Shan, J.; Aribi, A.; Garcia-Manero, G.; Jabbour, E.; Ravandi, F.; Cortes, J.; Davisson, J.; Issa, J. P. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007, 109 (2), 265-273. (Pubitemid 46106241)
30. Issa, J. P.; Garcia-Manero, G.; Giles, F. J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C. S.; Cortes, J.; Kantarjian, H. M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103 (5), 1635-1640. (Pubitemid 38268953)
31. Fandy, T. E.; Herman, J. G.; Kerns, P.; Jiemjit, A.; Sugar, E. A.; Choi, S. H.; Yang, A. S.; Aucott, T.; Dauses, T.; Odchimar-Reissig, R.; Licht, J.; McConnell, M. J.; Nasrallah, C.; Kim, M. K.; Zhang, W.; Sun, Y.; Murgo, A.; Espinoza-Delgado, I.; Oteiza, K.; Owoeye, I.; Silverman, L. R.; Gore, S. D.; Carraway, H. E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114 (13), 2764-2773.
32. Itzykson, R.; Thepot, S.; Quesnel, B.; Dreyfus, F.; Beyne-Rauzy, O.; Turlure, P.; Vey, N.; Recher, C.; Dartigeas, C.; Legros, L.; Delaunay, J.; Salanoubat, C.; Visanica, S.; Stamatoullas, A.; Isnard, F.; Marfaing-Koka, A.; de, B. S.; Chelghoum, Y.; Taksin, A. L.; Plantier, I.; Ame, S.; Boehrer, S.; Gardin, C.; Beach, C. L.; Ades, L.; Fenaux, P. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(2), 403-411.
33. Ravandi, F.; Issa, J. P.; Garcia-Manero, G.; O'Brien, S.; Pierce, S.; Shan, J.; Borthakur, G.; Verstovsek, S.; Faderl, S.; Cortes, J.; Kantarjian, H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009, 115 (24), 5746-5751.
34. Grovdal, M.; Karimi, M.; Khan, R.; Aggerholm, A.; Antunovic, P.; Astermark, J.; Bernell, P.; Engstrom, L. M.; Kjeldsen, L.; Linder, O.; Nilsson, L.; Olsson, A.; Holm, M. S.; Tangen, J. M.; Wallvik, J.; Oberg, G.; Hokland, P.; Jacobsen, S. E.; Porwit, A.; Hellstrom-Lindberg, E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br. J. Haematol. 2010, 150 (3), 293-302.
35. de Lima, M.; Giralt, S.; Thall, P. F.; de Padua, S. L.; Jones, R. B.; Komanduri, K.; Braun, T. M.; Nguyen, H. Q.; Champlin, R.; Garcia-Manero, G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116(23), 5420-5431.
36. Jabbour, E.; Giralt, S.; Kantarjian, H.; Garcia-Manero, G.; Jagasia, M.; Kebriaei, P.; de, P. L.; Shpall, E. J.; Champlin, R.; de, L. M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115 (9), 1899-1905.
37. Czibere, A.; Bruns, I.; Kroger, N.; Platzbecker, U.; Lind, J.; Zohren, F.; Fenk, R.; Germing, U.; Schroder, T.; Graf, T.; Haas, R.; Kobbe, G. 5- Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant. 2010, 45 (5), 872-876.
38. Thepot, S.; Itzykson, R.; Seegers, V.; Raffoux, E.; Quesnel, B.; Chait, Y.; Sorin, L.; Dreyfus, F.; Cluzeau, T.; Delaunay, J.; Sanhes, L.; Eclache, V.; Dartigeas, C.; Turlure, P.; Harel, S.; Salanoubat, C.; Kiladjian, J. J.; Fenaux, P.; Ades, L. Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. Blood 2010, 116(19), 3735-3742.
39. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.; Gattermann, N.; Germing, U.; Sanz, G.; List, A. F.; Gore, S.; Seymour, J. F.; Dombret, H.; Backstrom, J.; Zimmerman, L.; McKenzie, D.; Beach, C. L.; Silverman, L. R. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 2010, 28 (4), 562-569.
40. Cashen, A. F.; Schiller, G. J.; O'Donnell, M. R.; DiPersio, J. F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 2010, 28 (4), 556-561.
41. Sekeres, M. A.; List, A. F.; Cuthbertson, D.; Paquette, R.; Ganetzky, R.; Latham, D.; Paulic, K.; Afable, M.; Saba, H. I.; Loughran, T. P., Jr.; Maciejewski, J. P. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol. 2010, 28 (13), 2253-2258.
42. Borthakur, G.; Huang, X.; Kantarjian, H.; Faderl, S.; Ravandi, F.; Ferrajoli, A.; Torma, R.; Morris, G.; Berry, D.; Issa, J. P. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk. Lymphoma 2010, 51 (1), 73-78.
43. Nand, S.; Godwin, J.; Smith, S.; Barton, K.; Michaelis, L.; Alkan, S.; Veerappan, R.; Rychlik, K.; Germano, E.; Stiff, P. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk. Lymphoma 2008, 49 (11), 2141-2147.
44. Raza, A.; Mehdi, M.; Mumtaz, M.; Ali, F.; Lascher, S.; Galili, N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008, 113 (7), 1596-1604.
45. Sutherland, M. K.; Yu, C.; Anderson, M.; Zeng, W.; van, R. N.; Sievers, E. L.; Grewal, I. S.; Law, C. L. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2010, 2 (4).
46. Kantarjian, H. M.; O'Brien, S.; Cortes, J.; Giles, F. J.; Faderl, S.; Issa, J. P.; Garcia-Manero, G.; Rios, M. B.; Shan, J.; Andreeff, M.; Keating, M.; Talpaz, M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003, 98 (3), 522-528. (Pubitemid 36885992)
47. Oki, Y.; Kantarjian, H. M.; Gharibyan, V.; Jones, D.; O'brien, S.; Verstovsek, S.; Cortes, J.; Morris, G. M.; Garcia-Manero, G.; Issa, J. P. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007, 109 (5), 899-906. (Pubitemid 46333532)
48. Blum, K. A.; Liu, Z.; Lucas, D. M.; Chen, P.; Xie, Z.; Baiocchi, R.; Benson, D. M.; Devine, S. M.; Jones, J.; Andritsos, L.; Flynn, J.; Plass, C.; Marcucci, G.; Chan, K. K.; Grever, M. R.; Byrd, J. C. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br. J. Haematol. 2010, 150 (2), 189-195.
49. van Bemmel, D. M.; Brank, A. S.; Eritja, R.; Marquez, V. E.; Christman, J. K. DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem. Pharmacol. 2009, 78 (6), 633-641.
50. Candelaria, M.; Herrera, A.; Labardini, J.; Gonzalez-Fierro, A.; Trejo- Becerril, C.; Taja-Chayeb, L.; Perez-Cardenas, E.; Cruz-Hernandez, E.; Arias-Bofill, D.; Vidal, S.; Cervera, E.; Duenas-Gonzalez, A. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann. Hematol. 2011, 90(4), 379-387.
51. Marks, P. A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert. Opin. Investig. Drugs 2010, 19 (9), 1049-1066.
52. Lee, J. H.; Choy, M. L.; Ngo, L.; Foster, S. S.; Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U. S. A 2010, 107 (33), 14639-14644.
53. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26 (37), 5541-5552. (Pubitemid 47255934)
54. Reid, G.; Metivier, R.; Lin, C. Y.; Denger, S.; Ibberson, D.; Ivacevic, T.; Brand, H.; Benes, V.; Liu, E. T.; Gannon, F. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005, 24 (31), 4894-4907. (Pubitemid 41129094)
55. Joseph, J.; Mudduluru, G.; Antony, S.; Vashistha, S.; Ajitkumar, P.; Somasundaram, K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 2004, 23 (37), 6304-6315. (Pubitemid 39215301)
56. Foglietti, C.; Filocamo, G.; Cundari, E.; De, R. E.; Lahm, A.; Cortese, R.; Steinkuhler, C. Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J. Biol. Chem. 2006, 281 (26), 17968-17976. (Pubitemid 44035596)
57. Smith, C. L. A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays 2008, 30 (1), 15-24.
58. Buchwald, M.; Kramer, O. H.; Heinzel, T. HDACi--targets beyond chromatin. Cancer Lett. 2009, 280 (2), 160-167.
59. Gui, C. Y.; Ngo, L.; Xu, W. S.; Richon, V. M.; Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes inpromoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A 2004, 101 (5), 1241-1246. (Pubitemid 38182673)
60. Zhao, Y.; Lu, S.; Wu, L.; Chai, G.; Wang, H.; Chen, Y.; Sun, J.; Yu, Y.; Zhou, W.; Zheng, Q.; Wu, M.; Otterson, G. A.; Zhu, W. G. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol. Cell Biol. 2006, 26 (7), 2782-2790.
61. Spange, S.; Wagner, T.; Heinzel, T.; Kramer, O. H. Acetylation of nonhistone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41 (1), 185-198.
62. Simms-Waldrip, T.; Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A. K.; Fu, C.; Sakamoto, K. M. The aggresome pathway as a target for therapy in hematologic malignancies. Mol. Genet. Metab 2008, 94 (3), 283-286.
63. Nishioka, C.; Ikezoe, T.; Yang, J.; Takeuchi, S.; Koeffler, H. P.; Yokoyama, A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk. Res. 2008, 32 (9), 1382-1392.
64. Suzuki, T.; Yokozaki, H.; Kuniyasu, H.; Hayashi, K.; Naka, K.; Ono, S.; Ishikawa, T.; Tahara, E.; Yasui, W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer 2000, 88 (6), 992-997.
65. Dong, G.; Wang, L.; Wang, C. Y.; Yang, T.; Kumar, M. V.; Dong, Z. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J. Pharmacol. Exp. Ther. 2008, 325 (3), 978-984. (Pubitemid 351724333)
66. Nishioka, C.; Ikezoe, T.; Yang, J.; Komatsu, N.; Bandobashi, K.; Taniguchi, A.; Kuwayama, Y.; Togitani, K.; Koeffler, H. P.; Taguchi, H. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1- infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk. Res. 2008, 32 (2), 287-296. (Pubitemid 351215535)
67. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc. ) 2009, 45 (11), 787-795.
68. Kavanaugh, S. M.; White, L. A.; Kolesar, J. M. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am. J. Health Syst. Pharm. 2010, 67 (10), 793-797.
69. Zain, J. M.; O'Connor, O. Targeted treatment and new agents in peripheral Tcell lymphoma. Int. J. Hematol. 2010, 92 (1), 33-44.
70. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007, 12 (10), 1247-1252. (Pubitemid 350106355)
71. Crump, M.; Coiffier, B.; Jacobsen, E. D.; Sun, L.; Ricker, J. L.; Xie, H.; Frankel, S. R.; Randolph, S. S.; Cheson, B. D. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 2008, 19 (5), 964-969. (Pubitemid 351627315)
72. Duvic, M.; Becker J.C.; Dalle S. Phase II trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-cell Lymphoma (CTCL). Blood ASH Annual meeting proceedings 2008, Abs No 1005.
73. Duvic, M.; Olsen, E. A.; Breneman, D.; Pacheco, T. R.; Parker, S.; Vonderheid, E. C.; Abuav, R.; Ricker, J. L.; Rizvi, S.; Chen, C.; Boileau, K.; Gunchenko, A.; Sanz-Rodriguez, C.; Geskin, L. J. Evaluation of the longterm tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin. Lymphoma Myeloma. 2009, 9 (6), 412-416.
74. Olsen, E. A.; Kim, Y. H.; Kuzel, T. M.; Pacheco, T. R.; Foss, F. M.; Parker, S.; Frankel, S. R.; Chen, C.; Ricker, J. L.; Arduino, J. M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007, 25 (21), 3109-3115. (Pubitemid 47218059)
75. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J. J.; Allen, S. L.; Kirschbaum, M. H.; Zain, J.; Prince, H. M.; Leonard, J. P.; Geskin, L. J.; Reeder, C.; Joske, D.; Figg, W. D.; Gardner, E. R.; Steinberg, S. M.; Jaffe, E. S.; Stetler- Stevenson, M.; Lade, S.; Fojo, A. T.; Bates, S. E. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 2009, 27 (32), 5410-5417.
76. Campbell, R. A.; Sanchez, E.; Steinberg, J.; Shalitin, D.; Li, Z. W.; Chen, H.; Berenson, J. R. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur. J. Haematol. 2010, 84 (3), 201-211.
77. Chen, J.; Fiskus, W.; Eaton, K.; Fernandez, P.; Wang, Y.; Rao, R.; Lee, P.; Joshi, R.; Yang, Y.; Kolhe, R.; Balusu, R.; Chappa, P.; Natarajan, K.; Jillella, A.; Atadja, P.; Bhalla, K. N. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 2009, 113 (17), 4038-4048.
78. Dasmahapatra, G.; Lembersky, D.; Kramer, L.; Fisher, R. I.; Friedberg, J.; Dent, P.; Grant, S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115 (22), 4478-4487.
79. Heider, U.; von, M., I; Kaiser, M.; Rosche, M.; Sterz, J.; Rotzer, S.; Rademacher, J.; Jakob, C.; Fleissner, C.; Kuckelkorn, U.; Kloetzel, P. M.; Sezer, O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur. J. Haematol. 2008, 80 (2), 133-142.
80. Heider, U.; Rademacher, J.; Lamottke, B.; Mieth, M.; Moebs, M.; von, M., I; Assaf, C.; Sezer, O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol. 2009, 82 (6), 440-449.
81. Lee, C. K.; Wang, S.; Huang, X.; Ryder, J.; Liu, B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010, 296 (2), 233-240.
82. Paoluzzi, L.; Scotto, L.; Marchi, E.; Zain, J.; Seshan, V. E.; O'Connor, O. A. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin. Cancer Res. 2010, 16 (2), 554-565.
83. Rao, R.; Lee, P.; Fiskus, W.; Yang, Y.; Joshi, R.; Wang, Y.; Buckley, K.; Balusu, R.; Chen, J.; Koul, S.; Joshi, A.; Upadhyay, S.; Tao, J.; Sotomayor, E.; Bhalla, K. N. Co-treatment with heat shock protein 90 inhibitor 17- dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol. Ther. 2009, 8 (13), 1273-1280.
84. Yazbeck, V. Y.; Buglio, D.; Georgakis, G. V.; Li, Y.; Iwado, E.; Romaguera, J. E.; Kondo, S.; Younes, A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 2008, 36 (4), 443-450. (Pubitemid 351384743)
85. Zhang, Q. L.; Wang, L.; Zhang, Y. W.; Jiang, X. X.; Yang, F.; Wu, W. L.; Janin, A.; Chen, Z.; Shen, Z. X.; Chen, S. J.; Zhao, W. L. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23 (8), 1507-1514.
86. Shimizu, R.; Kikuchi, J.; Wada, T.; Ozawa, K.; Kano, Y.; Furukawa, Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010, 24(10), 1760-1768.
87. Mazumder, A.; Vesole, D. H.; Jagannath, S. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. Clin. Lymphoma Myeloma. Leuk. 2010, 10 (2), 149-151.
88. Badros, A.; Burger, A. M.; Philip, S.; Niesvizky, R.; Kolla, S. S.; Goloubeva, O.; Harris, C.; Zwiebel, J.; Wright, J. J.; Espinoza-Delgado, I.; Baer, M. R.; Holleran, J. L.; Egorin, M. J.; Grant, S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2009, 15 (16), 5250-5257.
89. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W. G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V. R.; Randolph, S. S.; Hardwick, J. S.; Reilly, J. F.; Chen, C.; Ricker, J. L.; Secrist, J. P.; Richon, V. M.; Frankel, S. R.; Kantarjian, H. M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111 (3), 1060-1066. (Pubitemid 351213383)
90. Garcia-Manero, G.; Assouline, S.; Cortes, J.; Estrov, Z.; Kantarjian, H.; Yang, H.; Newsome, W. M.; Miller, W. H., Jr.; Rousseau, C.; Kalita, A.; Bonfils, C.; Dubay, M.; Patterson, T. A.; Li, Z.; Besterman, J. M.; Reid, G.; Laille, E.; Martell, R. E.; Minden, M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112 (4), 981-989.
91. Gojo, I.; Jiemjit, A.; Trepel, J. B.; Sparreboom, A.; Figg, W. D.; Rollins, S.; Tidwell, M. L.; Greer, J.; Chung, E. J.; Lee, M. J.; Gore, S. D.; Sausville, E. A.; Zwiebel, J.; Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109 (7), 2781-2790 (Pubitemid 46482071)
92. Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J. J.; Pandolfi, P. P.; Nimer, S. D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 2008, 14 (3), 826-832. (Pubitemid 351231166)
93. Kuendgen, A.; Knipp, S.; Fox, F.; Strupp, C.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Gattermann, N. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. 2005, 84 Suppl 1, 61-66.
94. Kuendgen, A.; Schmid, M.; Schlenk, R.; Knipp, S.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Dohner, H.; Gattermann, N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106 (1), 112-119. (Pubitemid 43032555)
95. Cameron, E. E.; Bachman, K. E.; Myohanen, S.; Herman, J. G.; Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat. Genet. 1999, 21 (1), 103-107. (Pubitemid 29036293)
96. Voso, M. T.; Santini, V.; Finelli, C.; Musto, P.; Pogliani, E.; Angelucci, E.; Fioritoni, G.; Alimena, G.; Maurillo, L.; Cortelezzi, A.; Buccisano, F.; Gobbi, M.; Borin, L.; Di, T. A.; Zini, G.; Petti, M. C.; Martinelli, G.; Fabiani, E.; Fazi, P.; Vignetti, M.; Piciocchi, A.; Liso, V.; Amadori, S.; Leone, G. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin. Cancer Res. 2009, 15 (15), 5002-5007.
97. Gore, S. D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C. B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J. E.; Rudek, M. A.; Zhao, M.; Smith, B. D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L. J.; Herman, J. G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 66 (12), 6361-6369.
98. Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'brien, S.; Estey, E.; Bueso- Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108 (10), 3271-3279.
99. Almeida, A. M.; Murakami, Y.; Baker, A.; Maeda, Y.; Roberts, I. A.; Kinoshita, T.; Layton, D. M.; Karadimitris, A. Targeted therapy for inherited GPI deficiency. N. Engl. J. Med. 2007, 356 (16), 1641-1647. (Pubitemid 46631673)
100. Almeida, A. M.; Murakami, Y.; Layton, D. M.; Hillmen, P.; Sellick, G. S.; Maeda, Y.; Richards, S.; Patterson, S.; Kotsianidis, I.; Mollica, L.; Crawford, D. H.; Baker, A.; Ferguson, M.; Roberts, I.; Houlston, R.; Kinoshita, T.; Karadimitris, A. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nat. Med. 2006, 12 (7), 846-851. (Pubitemid 44050077)
101. Almeida, A.; Layton, M.; Karadimitris, A. Inherited glycosylphosphatidyl inositol deficiency: a treatable CDG. Biochim. Biophys. Acta 2009, 1792 (9), 874-880.
102. Ng, M. H.; Chung, Y. F.; Lo, K. W.; Wickham, N. W.; Lee, J. C.; Huang, D. P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997, 89 (7), 2500-2506. (Pubitemid 27143298)
103. Martinez-Delgado, B.; Richart, A.; Garcia, M. J.; Robledo, M.; Osorio, A.; Cebrian, A.; Rivas, C.; Benitez, J. Hypermethylation of P16ink4a and P15ink4b genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas. Br. J. Haematol. 2000, 109 (1), 97-103. (Pubitemid 30340584)
104. Martinez-Delgado, B.; Fernandez-Piqueras, J.; Garcia, M. J.; Arranz, E.; Gallego, J.; Rivas, C.; Robledo, M.; Benitez, J. Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997, 11 (3), 425-428. (Pubitemid 27120994)
105. Yang, Y.; Takeuchi, S.; Hofmann, W. K.; Ikezoe, T.; van Dongen, J. J.; Szczepanski, T.; Bartram, C. R.; Yoshino, N.; Taguchi, H.; Koeffler, H. P. Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk. Res. 2006, 30 (1), 98-102. (Pubitemid 41654711)
106. Nguyen, T. T.; Mohrbacher, A. F.; Tsai, Y. C.; Groffen, J.; Heisterkamp, N.; Nichols, P. W.; Yu, M. C.; Lubbert, M.; Jones, P. A. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 2000, 95 (9), 2990-2992. (Pubitemid 30235914)
107. Chen, H.; Wu, S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin Med. J. (Engl. ) 2002, 115 (7), 987-990. (Pubitemid 34830768)
108. Esteller, M.; Gaidano, G.; Goodman, S. N.; Zagonel, V.; Capello, D.; Botto, B.; Rossi, D.; Gloghini, A.; Vitolo, U.; Carbone, A.; Baylin, S. B.; Herman, J. G. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 2002, 94 (1), 26-32.
109. Matsushita, C.; Yang, Y.; Takeuchi, S.; Matsushita, M.; Van Dongen, J. J.; Szczepanski, T.; Bartram, C. R.; Seo, H.; Koeffler, H. P.; Taguchi, H. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol. Rep. 2004, 12 (1), 97-99.
110. Nakamichi, I.; Tomita, Y.; Zhang, B.; Sugiyama, H.; Kanakura, Y.; Fukuhara, S.; Hino, M.; Kanamaru, A.; Ogawa, H.; Aozasa, K. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann. Hematol. 2007, 86 (8), 557-564. (Pubitemid 47018473)
111. Amara, K.; Trimeche, M.; Ziadi, S.; Laatiri, A.; Hachana, M.; Korbi, S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann. Oncol. 2008, 19 (10), 1774-1786.
112. Martin, P.; Garcia-Cosio, M.; Santon, A.; Bellas, C. Aberrant gene promoter methylation in plasma cell dyscrasias. Exp. Mol. Pathol. 2008, 84 (3), 256-261.
113. Siu, L. L.; Chan, J. K.; Wong, K. F.; Choy, C.; Kwong, Y. L. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br. J. Haematol. 2003, 122 (1), 70-77. (Pubitemid 36819340)
114. Esteller, M.; Guo, M.; Moreno, V.; Peinado, M. A.; Capella, G.; Galm, O.; Baylin, S. B.; Herman, J. G. Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res. 2002, 62 (20), 5902-5905. (Pubitemid 35204752)
115. Galm, O.; Yoshikawa, H.; Esteller, M.; Osieka, R.; Herman, J. G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101 (7), 2784-2788. (Pubitemid 36857644)
116. Chen, C. Y.; Tsay, W.; Tang, J. L.; Shen, H. L.; Lin, S. W.; Huang, S. Y.; Yao, M.; Chen, Y. C.; Shen, M. C.; Wang, C. H.; Tien, H. F. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes. Cancer 2003, 37 (3), 300-305. (Pubitemid 36667568)
117. Seidl, S.; Ackermann, J.; Kaufmann, H.; Keck, A.; Nosslinger, T.; Zielinski, C. C.; Drach, J.; Zochbauer-Muller, S. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004, 100 (12), 2598-2606. (Pubitemid 38715765)
118. Greco, M.; D'Alo, F.; Scardocci, A.; Criscuolo, M.; Fabiani, E.; Guidi, F.; Di, R. A.; Migliara, G.; Pagano, L.; Fianchi, L.; Chiusolo, P.; Hohaus, S.; Leone, G.; Voso, M. T. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol. Dis. 2010, 45 (3), 181-185.
119. Corn, P. G.; Smith, B. D.; Ruckdeschel, E. S.; Douglas, D.; Baylin, S. B.; Herman, J. G. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin. Cancer Res. 2000, 6 (11), 4243-4248.
120. Watanabe, T.; Kato, H.; Kobayashi, Y.; Yamasaki, S.; Morita-Hoshi, Y.; Yokoyama, H.; Morishima, Y.; Ricker, J. L.; Otsuki, T.; Miyagi-Maesima, A.; Matsuno, Y.; Tobinai, K. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010, 101 (1), 196-200.
121. Richardson, P.; Mitsiades, C.; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C.; Atkins, B.; Fearen, I.; Anderson, K.; Siegel, D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 2008, 49 (3), 502-507. (Pubitemid 351298334)
122. Buglio, D.; Georgakis, G. V.; Hanabuchi, S.; Arima, K.; Khaskhely, N. M.; Liu, Y. J.; Younes, A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112 (4), 1424-1433.
123. O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; MacGregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; Zelenetz, A. D.; Frankel, S.; Richon, V.; Marks, P.; Kelly, W. K. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006, 24 (1), 166-173. (Pubitemid 46630509)
124. Richter-Larrea, J. A.; Robles, E. F.; Fresquet, V.; Beltran, E.; Rullan, A. J.; Agirre, X.; Calasanz, M. J.; Panizo, C.; Richter, J. A.; Hernandez, J. M.; Roman-Gomez, J.; Prosper, F.; Martinez-Climent, J. A. Reversion of epigenetically-mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010, 116(14), 2531-2542.
125. Khan, S. B.; Maududi, T.; Barton, K.; Ayers, J.; Alkan, S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol. 2004, 125 (2), 156-161. (Pubitemid 38534966)
126. Shao, W.; Growney, J. D.; Feng, Y.; O'Connor, G.; Pu, M.; Zhu, W.; Yao, Y. M.; Kwon, P.; Fawell, S.; Atadja, P. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int. J. Cancer 2010, 127 (9), 2199-2208.
127. Sanchez, E.; Shen, J.; Steinberg, J.; Li, M.; Wang, C.; Bonavida, B.; Chen, H.; Li, Z. W.; Berenson, J. R. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk. Res. 2011, 35(3), 373-379.
128. Ocio, E. M.; Vilanova, D.; Atadja, P.; Maiso, P.; Crusoe, E.; Fernandez- Lazaro, D.; Garayoa, M.; San-Segundo, L.; Hernandez-Iglesias, T.; de, A. E.; Shao, W.; Yao, Y. M.; Pandiella, A.; San-Miguel, J. F. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95 (5), 794-803.
129. Gimsing, P.; Hansen, M.; Knudsen, L. M.; Knoblauch, P.; Christensen, I. J.; Ooi, C. E.; Buhl-Jensen, P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 2008, 81 (3), 170-176.
130. Mandl-Weber, S.; Meinel, F. G.; Jankowsky, R.; Oduncu, F.; Schmidmaier, R.; Baumann, P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol. 2010, 149 (4), 518-528.
131. Stuhmer, T.; Arts, J.; Chatterjee, M.; Borawski, J.; Wolff, A.; King, P.; Einsele, H.; Leo, E.; Bargou, R. C. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br. J. Haematol. 2010, 149 (4), 529-536.
132. Pilatrino, C.; Cilloni, D.; Messa, E.; Morotti, A.; Giugliano, E.; Pautasso, M.; Familiari, U.; Cappia, S.; Pelicci, P. G.; Lo, C. F.; Saglio, G.; Guerrasio, A. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and alltrans retinoic acid. Cancer 2005, 104 (1), 101-109. (Pubitemid 40847757)
133. Fandy, T. E.; Herman, J. G.; Kerns, P.; Jiemjit, A.; Sugar, E. A.; Choi, S. H.; Yang, A. S.; Aucott, T.; Dauses, T.; Odchimar-Reissig, R.; Licht, J.; McConnell, M. J.; Nasrallah, C.; Kim, M. K.; Zhang, W.; Sun, Y.; Murgo, A.; Espinoza-Delgado, I.; Oteiza, K.; Owoeye, I.; Silverman, L. R.; Gore, S. D.; Carraway, H. E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114 (13), 2764-2773.